Current Status and Future Prospects of Treatment for EGFR-Positive Non-Small Cell Lung Cancer After Resistance to EGFR-TKI
10.3971/j.issn.1000-8578.2025.24.1209
- VernacularTitle:EGFR阳性非小细胞肺癌EGFR-TKI耐药后的治疗现状及未来展望
- Author:
Yiming ZENG
1
;
Wenfeng FANG
1
;
Li ZHANG
1
Author Information
1. Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China.
- Publication Type:SPECIALFEATURE
- Keywords:
EGFR-mutant NSCLC;
EGFR-TKI resistance;
Targeted therapy;
Immunotherapy;
Novel drugs
- From:
Cancer Research on Prevention and Treatment
2025;52(6):429-435
- CountryChina
- Language:Chinese
-
Abstract:
EGFR-mutant non-small cell lung cancer (NSCLC) is a common type of lung cancer, with EGFR tyrosine kinase inhibitors (EGFR-TKIs) being the standard first-line treatment. However, most patients with NSCLC eventually develop resistance to EGFR-TKIs. Studies on the mechanism underlying EGFR-TKI resistance have driven the development of personalized and precision medicine. Current strategies to address resistance include targeted therapy, immunotherapy, and novel drug treatments. Selecting the appropriate personalized treatment plan is crucial for improving the survival rate and quality of life of patients with EGFR-mutant NSCLC. Thus, this study provides a brief review of the current status and future perspectives in the treatment of EGFR-mutant NSCLC after progression on EGFR-TKI therapy.
